Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Galapagos’ pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, osteoarthritis and other indications. Our target discovery platform has delivered three novel mechanisms showing promising patient results in, respectively, inflammatory diseases, idiopathic fibrosis and atopic dermatitis. Our ambition is to become a leading global biopharmaceutical company, focused on the development and commercialization of innovative medicines that will improve people’s lives.
The Galapagos group, including fee-for-service subsidiary Fidelta, has approximately 750 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, Switzerland, Croatia and the United States. More info at www.glpg.com
Director Corporate Business Development, Galapagos
Paul joined Galapagos early 2016 as Head of Corporate Development. In this role he leads Galapagos’ licensing, partnering efforts and M&A. Prior to Galapagos, he worked at boutique investment bank Kempen & Co in Amsterdam, where was responsible for broking and dealing of European pharma & biotech stocks to institutional investors in Europe and the US. At Kempen, Paul was instrumental in over a dozen capital markets transactions, raising over €0.5bn. Paul studied medicine and holds a PhD in Gynaecological Oncology from the Erasmus University Medical Centre in Rotterdam, The Netherlands.